Top Canadian Cannabis Penny Stocks to Watch This Month

The cannabis sector continues to attract investors seeking growth opportunities in 2026. Marijuana penny stocks remain volatile. However, they also offer strong upside potential when market momentum improves. Many cannabis companies are now focusing on profitability, stronger balance sheets, and international growth opportunities. Because of this, traders continue monitoring the sector closely for breakout setups.

Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets

NASDAQ | TSX: ACB Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats Scaled launches across Canada, Europe and Australia support growing demand in regulated international medical markets Continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network EDMONTON, AB, April 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, is significantly expanding its global medical cannabis portfolio, with new product launches rolling out across Canada, Europe and Australia. The company continues to shape the global cannabis landscape by introducing new products and formats around the world.

PRNewsWire • Apr 28, 2026

Aurora Cannabis: Why I Like This Stock

Aurora Cannabis Inc. has transformed into a cannabis-focused company with improving international revenue and margins, while spinning off its Bevo division. ACB's balance sheet now shows net cash of C$46.7 million, achieved through equity sales, and enterprise value trades at just 3.8x projected FY27 adjusted EBITDA. I target a 64% upside for ACB to US$5.58 within a year, based on a 6x FY28 adjusted EBITDA multiple, with the stock trading below tangible book value.

Seeking Alpha • Apr 24, 2026

'GIANT STEP FORWARD': Reclassification of medical cannabis lauded

Trulieve founder and CEO Kim Rivers discusses the impact of Trump's administration reclassifying state-licensed medical cannabis from Schedule 1 to Schedule 3 on 'Varney & Co.' 00:00 Introduction & Reclassification Impact 02:19 Tax Reform & Business Normalization 03:18 Edibles vs. Vapes for Medical Use

Fox Business • Apr 24, 2026

'Big Business Opportunity': Cannabis CEO Celebrates DOJ Easing Regulations On Medical Marijuana

The Trump administration reclassified medical marijuana as a less dangerous drug on Thursday. FDA-approved and state-licensed medical marijuana was rescheduled from a Schedule I drug to the less strict Schedule III category.

Forbes • Apr 23, 2026

Cannabis rescheduling fuels optimism across industry

The U.S. Department of Justice is immediately loosening restrictions on some marijuana products and accelerating the process of reclassifying the drug as less dangerous in one of the biggest changes to ​U.S. drug policy in decades.

Reuters • Apr 23, 2026

The cannabis rescheduling is causing celebration — and confusion — as marijuana stocks sell off

Marijuana stocks sold off Thursday, after acting U.S. Attorney General Todd Blanche signed an order rescheduling Food and Drug Administration-approved and state-licensed medical cannabis products as a less harmful substance — a move that led to celebration but also confusion among industry observers.

Market Watch • Apr 23, 2026

Finally. Marijuana Gets Reclassified, but Are Pot Stocks Still Too Risky?

Markets don't usually wait for permission — they anticipate it.

24/7 Wall Street • Apr 23, 2026

Why are cannabis stocks surging today?

Shares of major cannabis companies rallied sharply on Wednesday after reports suggested the Trump Administration could soon move to reclassify marijuana, a long-awaited step that investors believe could ease regulatory pressures on the sector. The gains were led by Curaleaf Holdings, which surged more than 27%.

Invezz • Apr 22, 2026

Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets

NASDAQ | TSX: ACB EDMONTON, AB, April 15, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions (the "Transaction").

PRNewsWire • Apr 15, 2026